Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

Biopsy report: New and established Disease3rd H-ECCO IBD Masterclass
Year: 2018
Authors: Feakins Roger
Files: 1
Case-based discussion: Optimal management of patient with severe Crohn’s Disease treated with anti-TNF agents 16th IBD Intensive Advanced Course
Year: 2018
Authors: Fitzpatrick Michael, Travis Simon
Files: 1
Childhood onset PSC: A distinct IBD phenotype?5th P-ECCO Educational Course
Year: 2018
Authors: van Rheenen Patrick
Files: 1
Clinical grades and scores in IBD3rd H-ECCO IBD Masterclass
Year: 2018
Authors: Lindsay James
Files: 1
CMV: Identification and quantification3rd H-ECCO IBD Masterclass
Year: 2018
Authors: Villanacci Vincenzo
Files: 1
Colorectal neoplasia in IBD3rd H-ECCO IBD Masterclass
Year: 2018
Authors: Svrcek Magali
Files: 1
Complications arising out of (mal)nutritionally induced Refractory Disease3rd D-ECCO Workshop
Year: 2018
Authors: Mantzaris Gerassimos
Files: 1
Datasets for IBD: Could they be useful?3rd H-ECCO IBD Masterclass
Year: 2018
Authors: Feakins Roger
Files: 1
Diagnosis, anatomy and physiology in IBD9th N-ECCO School
Year: 2018
Authors: Ferrante Marc
Files: 1
Dietary pathogenesis in Ulcerative Colitis3rd D-ECCO Workshop
Year: 2018
Authors: Sarbagili Chen
Files: 1
Dietary supplements in IBD3rd D-ECCO Workshop
Year: 2018
Authors: Sigall-Boneh Rotem
Files: 1
Does size matter? How long should the Pouch be?7th S-ECCO IBD Masterclass
Year: 2018
Authors: Colombo Francesco
Files: 1
DOP001: Effectiveness and safety of vedolizumab in anti-TNF naïve patients with Inflammatory Bowel Disease - a multicentre retrospective studyECCO'18 Vienna
Year: 2018
Authors: Kopylov Uri
Files: 1
DOP002:Vedolizumab treatment persistence up to 3 years: Post hoc analysis in vedolizumab-naïve patients from the GEMINI LTS studyECCO'18 Vienna
Year: 2018
Authors: Vermeire Séverine
Files: 1
DOP003: Ustekinumab induces clinical and biological remission in biologic refractory Crohn's Disease patients: A real world belgian cohort studyECCO'18 Vienna
Year: 2018
Authors: Liefferinckx Claire
Files: 1
DOP004: Long-term safety of adalimumab in patients with Moderate to Severe Ulcerative Colitis: Interim results of a non-interventional registry, LEGACYECCO'18 Vienna
Year: 2018
Authors: Bossuyt Peter
Files: 1
DOP005: Safety of vedolizumab in patients naïve to treatment with TNF antagonists compared with patients with prior use of TNF antagonistsECCO'18 Vienna
Year: 2018
Authors: Russell Cohen
Files: 1
DOP006: A multicentre cohort study to assess the safety of vedolizumab for Inflammatory Bowel DiseaseECCO'18 Vienna
Year: 2018
Authors: Dulai Parambir S
Files: 1
DOP007: Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha resistant Inflammatory Bowel DiseaseECCO'18 Vienna
Year: 2018
Authors: Bor Renata
Files: 1
DOP008: Safety of adalimumab in children and adolescents with Moderate to Severe Crohn’s Disease: Interim results of the CAPE registryECCO'18 Vienna
Year: 2018
Authors: Turner Dan
Files: 1